Last 185.00 GBp
Change Today 0.00 / 0.00%
Volume 0.0
INS On Other Exchanges
As of 11:35 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

instem plc (INS) Snapshot

185.00 GBp
Previous Close
185.00 GBp
Day High
185.00 GBp
Day Low
185.00 GBp
52 Week High
04/1/14 - 197.50 GBp
52 Week Low
04/22/13 - 107.50 GBp
Market Cap
Average Volume 10 Days
0.05 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for INSTEM PLC (INS)

Related News

No related news articles were found.

instem plc (INS) Related Businessweek News

No Related Businessweek News Found

instem plc (INS) Details

Instem Plc provides a portfolio of software solutions to the life sciences market worldwide. The company offers pre-clinical study management solutions used in the early development healthcare market for the data collection, management, and analysis activities. Its solutions include Provantis, a Windows-based system for organizations and universities engaged in non-clinical evaluation studies; TRP, a solution for pharmaceutical, chemical, and contract research laboratory corporations; DISPENSE, a computer based system for test item control; Logbook, a solution to replace GLP and Non-GLP paper data; Submit, an integrated nonclinical solution suite; and SENDView, a data review application. The company also offers Animal Care Information System, a solution for managing animal facility; Centrus, a solution suite that provides early drug development information from various sources; Safety Intelligence Program, a Web-based database of toxicology and pathology intelligence; SRS, a data integration platform; Metawise, an ontology solution; and OmniViz, a data mining and visual analytics tool. In addition, it offers a range of services comprising project management, installation, validation, data management, training, solution development, remote systems, client support, and specialized solutions. Further, the company provides software-as-a-service solutions. Instem Plc has strategic partnerships with Microsoft, Oracle, CTCLS, Datapipe, SAS, Business Objects, and Asta Development. Its customer base consists of the pharmaceutical, chemical, and contract research organizations, including government and privately funded programs across sites. The company was founded in 1969 and is headquartered in Stone, the United Kingdom.

Founded in 1969

instem plc (INS) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 143.0K GBP
Chief Financial Officer, Secretary and Direct...
Total Annual Compensation: 82.0K GBP
Compensation as of Fiscal Year 2012.

instem plc (INS) Key Developments

National Institute of Environmental Health Sciences Extends Use of Instem plc's Provantis Preclinical Software Across Additional Sites and Users

Instem plc announced that the National Institute of Environmental Health Sciences has exercised the year two option for Instem's Provantis preclinical software suite via SaaS (Software-as-a-Service), supporting National Toxicology Program studies. It has also exercised options to add two further operational sites and 100 further Provantis users. The value of this latest extension to the contract, which was signed in February 2013, is approximately $1.3 million and the potential remains to extend and expand the agreement up to a further 8 years, giving a possible total contract value for all 10 years of between $6.5 million -$7.6 million. Having also added two additional sites during 2013, there are now 6 sites licensed under the agreement. The contract includes the ability to licence usage at 6 additional sites (maximum 12 sites in total) on the same terms, which could result in a further material increase in revenue.

Instem plc Reports Unaudited Consolidated Earnings Results for the Year Ended December 31, 2013

Instem plc reported unaudited consolidated earnings results for the year ended December 31, 2013. For the year, revenue was GBP 11.361 million against GBP 10.661 million a year ago. Profit from operation was GBP 0.760 million against GBP 1.158 million a year ago. Profit before taxation was GBP 0.698 million against GBP 1.252 million a year ago. Profit for the year attributable to the owner of the parent company was GBP 0.529 million or 4.5 pence per basic and diluted share against GBP 1.044 million or 8.9 pence per basic and diluted share a year ago. Net cash generated from operating activities was GBP 2.044 million against net cash used in operating activities of GBP 0.078 million a year ago. Purchase of intangible assets was GBP 0.407 million against GBP 0.328 million a year ago. Purchase of property, plant and equipment was GBP 0.262 million against GBP 0.158 million a year ago. Adjusted operating profit increased 8% to GBP 1.5 million compared to GBP 1.3 million in 2012. Adjusted earnings per share were 8.6 pence compared to 7.8 pence in 2012. Growth in Revenue was principally driven from the UK, with an increase from GBP 1.3 million in 2012 to GBP 2.5 million, driven by new business orders for ALPHADAS received from Retroscreen Virology.

Instem plc, 2013 Earnings Call, Mar 26, 2014

Instem plc, 2013 Earnings Call, Mar 26, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INS:LN 185.00 GBp 0.00

INS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INS.
View Industry Companies

Industry Analysis


Industry Average

Valuation INS Industry Range
Price/Earnings 41.8x
Price/Sales 1.9x
Price/Book 4.4x
Price/Cash Flow 19.6x
TEV/Sales 2.0x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSTEM PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at